KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets: 2009-2025

Historic Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • Halozyme Therapeutics' Current Assets rose 17.90% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17.90%. This contributed to the annual value of $1.1 billion for FY2024, which is 45.41% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Current Assets of $1.3 billion as of Q3 2025, which was up 18.36% from $1.1 billion recorded in Q2 2025.
  • Halozyme Therapeutics' Current Assets' 5-year high stood at $1.3 billion during Q3 2025, with a 5-year trough of $541.9 million in Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Current Assets value was $987.8 million (recorded in 2024), while the average stood at $981.2 million.
  • In the last 5 years, Halozyme Therapeutics' Current Assets skyrocketed by 103.91% in 2021 and then crashed by 45.79% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Current Assets (Quarterly) stood at $926.3 million in 2021, then declined by 20.22% to $739.0 million in 2022, then rose by 1.00% to $746.4 million in 2023, then surged by 45.41% to $1.1 billion in 2024, then increased by 17.90% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.3 billion during Q1 2025.